Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1432-0584
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study ; volume:99 ; number:7 ; day:1 ; month:6 ; year:2020 ; pages:1615-1625 ; date:7.2020
Annals of hematology ; 99, Heft 7 (1.6.2020), 1615-1625, 7.2020

Creator
Zerbit, Jeremie
Chevret, Sylvie
Bernard, Sophie
Kroemer, Marie
Ablard, Charlotte
Harel, Stephanie
Brice, Pauline
Madelaine, Isabelle
Thieblemont, Catherine
Contributor
SpringerLink (Online service)

DOI
10.1007/s00277-020-04045-y
URN
urn:nbn:de:101:1-2020082120233823141072
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:57 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Zerbit, Jeremie
  • Chevret, Sylvie
  • Bernard, Sophie
  • Kroemer, Marie
  • Ablard, Charlotte
  • Harel, Stephanie
  • Brice, Pauline
  • Madelaine, Isabelle
  • Thieblemont, Catherine
  • SpringerLink (Online service)

Other Objects (12)

Ibrutinib for B cell malignancies

Ibrutinib for B cell malignancies

Alternative analytical methods for ibrutinib quantification in pharmaceutical formulation: A statistical comparison

Alternative analytical methods for ibrutinib quantification in pharmaceutical formulation: A statistical comparison

Target Identification and Validation in Ibrutinib-treated Mantle Cell Lymphoma

Target Identification and Validation in Ibrutinib-treated Mantle Cell Lymphoma

CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma

CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma

Drug Review: Ibrutinib

Drug Review: Ibrutinib

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study

Mixed Diffuse and Tumoral Form of Bing-Neel Syndrome Successfully Treated with Ibrutinib

Mixed Diffuse and Tumoral Form of Bing-Neel Syndrome Successfully Treated with Ibrutinib

IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice

IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice

Extrahepatic metabolism of ibrutinib

Extrahepatic metabolism of ibrutinib

Ibrutinib/Rituximab oder Ibrutinib allein – es kommt darauf an : Chronische lymphatische Leukämie

Ibrutinib/Rituximab oder Ibrutinib allein – es kommt darauf an : Chronische lymphatische Leukämie

The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib

The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia

Related objects